Media Releases › Sienna Cancer Diagnostics

Highlights:

• BARD1 Life Sciences Ltd (BARD1) and Sienna Cancer Diagnostics Ltd (Sienna) agreeto merge.
• Values each Sienna share at $0.061(68% premium to Sienna’s 3 month VWAP of$0.036).
• Transformational transaction combining two complementary cancer diagnosticbusinesses positioning the merged company to consolidate the Australian cancerdiagnostics market.
• The merged entity will have a strong balance sheet, an expanded portfolio of cancerdiagnostic technologies and a broader management team to help bring theseproducts to market.
• Merged company will focus on delivering innovative cancer diagnostics to addressunmet needs in early cancer detection to help save patients’ lives and increaseshareholder value.